Innate Pharma reports H1 2026 net loss of €19.6 million amid cash declineSep 17Quarterly updateInnate Pharma
Innate Pharma reports H1 2026 results, confirms Sobi deal launch and cash runway into 2028Sep 17PartnershipInnate Pharma
Innate Pharma partners with Sobi to license lacutamab in T-cell lymphomaAug 10Clinical readoutInnate Pharma
Innate Pharma completes enrollment in Phase 1 study of Nectin-4 ADC IPH4502Jul 21Clinical readoutInnate PharmaIPH4502
Sign in